Associated tags: Drug development, Patient, Pharmaceutical industry, Science, Research, Health, University, Biotechnology, Pharmaceutical, Fine chemical, Cancer, Clinical trial, Veteran, Clinical Trials, Oncology, General Health, PPD
Locations: MASSACHUSETTS, NORTH AMERICA, EUROPE, UNITED STATES, TEXAS
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
University,
Biomedical engineering,
PPD,
Ophthalmology,
Patient,
Chemical engineering,
Multimedia,
Clinical trial,
Therapy,
Thermo Fisher Scientific,
Growth,
Pharmaceutical industry LumaBridge , a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Chief Executive Officer, President and member of the Board of Directors.
Key Points:
- LumaBridge , a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Chief Executive Officer, President and member of the Board of Directors.
- View the full release here: https://www.businesswire.com/news/home/20240424682595/en/
Todd joined LumaBridge in April 2023 to head the company’s business development organization, and he quickly made a significant impact as a member of the executive team in driving business growth and process improvements.
- Prior to joining LumaBridge, Todd held various leadership roles in operations and portfolio management with a focus on the biotech customer at PPD, a Thermo Fisher Scientific company.
- Todd began his career in clinical research at Rx Development Resources, the CRO division of Sirion Therapeutics.
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
General Health,
Health,
PPD,
Culture,
Professional,
ICON,
Amanda,
Multimedia,
ORA,
University,
Nursing,
RN,
Texas A&M University,
Suffolk University,
Environment,
ChromeOS LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to novel cancer therapies, today announced the appointment of Amanda Ferrier as Chief Operating Officer.
Key Points:
- LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to novel cancer therapies, today announced the appointment of Amanda Ferrier as Chief Operating Officer.
- View the full release here: https://www.businesswire.com/news/home/20230807587831/en/
Amanda Ferrier Joins LumaBridge as Chief Operating Officer (Photo: Business Wire)
Ms. Ferrier brings over 20 years of clinical operations experience in oncology to LumaBridge.
- "Amanda is a great addition to the LumaBridge team as we continue to grow our oncology focused CRO," said David Boyle, Chief Executive Officer of LumaBridge.
- The company has a strong scientific foundation and an extremely talented management team that uniquely positions LumaBridge within the CRO environment,” said Amanda Ferrier.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
PPD,
Business development,
Laboratory,
Medical Affairs Bureau,
University,
Clinical trial,
Thermo Fisher Scientific,
Biomedical engineering,
Alcon,
Chemical engineering,
Ophthalmology,
Growth,
Therapy,
Fine chemical LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Vice President and Head of Business Development.
Key Points:
- LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Vice President and Head of Business Development.
- Todd brings nearly 20 years of client services, commercial and clinical operations experience to LumaBridge.
- "We are thrilled to welcome Todd to the LumaBridge team," said David Boyle, Chief Executive Officer of LumaBridge.
- “I’m honored to be joining LumaBridge at this exciting stage of growth in the company’s evolution,” said Todd Lehman.
Retrieved on:
Tuesday, November 8, 2022
Surgical oncology,
MBA,
Memorial Sloan Kettering Cancer Center,
Hospital,
United States service academies,
University,
Institute,
Uniformed Services University of the Health Sciences,
Patient,
SAN,
Bon,
Journal of Surgical Oncology,
Journal,
Program,
FACS,
Triple accreditation,
Drug development,
GlaxoSmithKline,
MSKCC,
Saint Mary's Hospital,
Medicine,
Maryland School,
Walter Reed Army Medical Center,
Clinical Medicine Insights: Oncology,
Harvard Business School,
Partnership,
Master of Science,
Science,
Memorial,
European Journal of Cancer,
Research,
CRO,
Outline of health sciences,
Health,
Strategic planning,
Pharmaceutical industry,
Management,
MD,
Cancer,
Pharmacy SAN ANTONIO, Nov. 8, 2022 /PRNewswire/ -- LumaBridge (formerly known as Cancer Insight), a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, welcomes a new chief medical officer, Alexander Stojadinovic, MD, MBA, MSc, FACS.
Key Points:
- SAN ANTONIO, Nov. 8, 2022 /PRNewswire/ -- LumaBridge (formerly known as Cancer Insight), a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, welcomes a new chief medical officer, Alexander Stojadinovic, MD, MBA, MSc, FACS.
- He brings to LumaBridge his extensive experience in strategic planning, program development, team building, operations, and research and development.
- Dr. Stojadinovic has served as senior medical director in oncology clinical development at GlaxoSmithKline, as medical director of healthcare management services for Amerigroup Texas, and as a consulting surgical oncologist and healthcare executive.
- "We are thrilled to welcome Alex to the team," said George E. Peoples, MD, FACS, founder, chief scientific officer, and executive chairman of LumaBridge.
As LumaBridge, the company will continue to build on its legacy of supporting the development of novel immunotherapies in the fight against cancer.
Key Points:
- As LumaBridge, the company will continue to build on its legacy of supporting the development of novel immunotherapies in the fight against cancer.
- LumaBridge, formerly Cancer Insight, announces the rebranding of their specialty clinical research organization.
- LumaBridge was founded in 2014 as Cancer Insight by veterans Dr. George Peoples and Dan Hargrove, who bring more than 30 years of combined experience in academic and military research.
- The LumaBridge name change reflects the company's vision for working hand-in-hand with emerging biopharmacompaniesandlighting apathforwardtothedevelopmentoflife-changingimmunotherapy cancer treatments.
Research,
Finance,
Clinical Trials,
Professional Services,
Biotechnology,
Health,
Pharmaceutical,
General Health,
Science,
Partnership,
Integrated DNA Technologies,
Cancer,
Technology,
Veteran,
LinkedIn,
Partner,
Integration,
Summit,
Clinical trial,
Growth,
Drug development,
Patient,
CRO,
Pharmaceutical industry,
Fine chemical,
Takara Holdings LumaBridge (formerly known as Cancer Insight), an oncology-focused clinical research organization (CRO), today announced a majority growth investment from global investor Summit Partners .
Key Points:
- LumaBridge (formerly known as Cancer Insight), an oncology-focused clinical research organization (CRO), today announced a majority growth investment from global investor Summit Partners .
- Summit Partners has a long history of partnering with leading companies in healthcare and life sciences, helping to accelerate their growth and development, added Dave Boyle , chief executive officer of LumaBridge.
- Founded in 1984, Summit Partners is a global alternative investment firm that is currently managing more than $35 billion in capital dedicated to growth equity, fixed income, and public equity opportunities.
- Summit invests across growth sectors of the economy and has invested in more than 550 companies in healthcare, technology, and other growth industries.
